Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.

被引：1
|
作者：
Biran, Noa
Siegel, David Samuel DiCapua
Berdeja, Jesus G.
Raje, Noopur S.
Cornell, Robert F.
Alsina, Melissa
Kovacsovics, Tibor
Fang, Belle
Kimball, Amy
Landgren, Carl Ola
机构：
[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] Huntsman Canc Inst, Salt Lake City, UT USA
[7] Amgen Inc, Thousand Oaks, CA 91320 USA
[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.8022
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8022
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
    Biran, Noa
    Siegel, David
    Berdeja, Jesus G.
    Raje, Noopur
    Cornell, Robert Frank
    Alsina, Melissa
    Kovacsovics, Tibor
    Fang, Belle
    Kimball, Amy S.
    Landgren, Ola
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (07) : 794 - 802
  • [2] A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
    Gasparetto, Cristina
    Schiller, Gary J.
    Callander, Natalie Scott
    Lentzsch, Suzanne
    Tuchman, Sascha A.
    Bahlis, Nizar
    White, Darrell J.
    Chen, Christine I.
    Sutherland, Heather J.
    Baljevic, Muhamed
    Kotb, Rami
    Leblanc, Richard
    Sebag, Michael
    Venner, Christopher P.
    Bensinger, William I.
    Sheehan, Heidi
    Chai, Yi
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    Lipe, Brea C.
    BLOOD, 2019, 134
  • [3] Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)
    Chari, Ajai
    Lonial, Sagar
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    Oriol, Albert
    Otero, Paula Rodriguez
    Pineiro, Luis
    Jakubowiak, Andrzej
    Olyslager, Yunsi
    Wang, Jianping
    Nnane, Ivo
    Ukropec, Jon
    Shreeve, Martin
    Qi, Ming
    Moreau, Philippe
    BLOOD, 2019, 134
  • [4] A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma
    Martin, Thomas
    Baz, Rachid
    Benson, Don M.
    Lendvai, Nikoletta
    Wolf, Jeffrey
    Munster, Pamela
    Lesokhin, Alexander M.
    Wack, Claudine
    Charpentier, Eric
    Campana, Frank
    Vij, Ravi
    BLOOD, 2017, 129 (25) : 3294 - 3303
  • [5] A REAL-WORLD EFFICACY AND SAFETY ANALYSIS OF CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE (KRD) COMBINATION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Caratozzolo, I.
    Tacchetti, P.
    Zambello, R.
    Pantani, L.
    Antonioli, E.
    Mancuso, K.
    Buda, G.
    Rocchi, S.
    Canepa, L.
    Rizzello, I.
    Gamberi, B.
    Barila, G.
    Testoni, N.
    Marzocchi, G.
    Zamagni, E.
    Cavo, M.
    HAEMATOLOGICA, 2019, 104 : 66 - 66
  • [6] A Phase 1b Study Investigating Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma
    Biran, Noa
    Siegel, David S.
    Berdeja, Jesus G.
    Faber, Edward
    Seneviratne, Lasika
    Alsina, Melissa
    Bensinger, William
    Kimball, Amy S.
    Zhou, Kefei
    Landgren, Ola
    BLOOD, 2016, 128 (22)
  • [7] Dacetuzurmab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study
    Agura, Edward
    Niesvizky, Ruben
    Matous, Jeffrey
    Munshi, Nikhil
    Hussein, Mohamad
    Parameswaran, Ramakrishnan V.
    Tarantolo, Stefano
    Whiting, Nancy C.
    Drachman, Jonathan G.
    Zonder, Jeffrey A.
    BLOOD, 2009, 114 (22) : 1120 - 1121
  • [8] Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma
    Garcia-Guinon, Antoni
    Charry, Paola Andrea
    Jimenez, Maria
    Sarra, Josep
    Delgado, Izarbe
    de la Torre, Laura Segura
    Santaliestra, Marta
    Garcia-Pintos, Marta
    Gonzalez, Yolanda
    Senin, Alicia
    Motllo, Cristina
    Abella, Eugenia
    Cabezudo, Elena
    Granell, Miquel
    Sancho, Esther
    Herranz, Maria Jose
    Seres, Yasmina
    Gironella, Mercedes
    Soler, Juan Alfons
    Marti-Tutusaus, Josep Maria
    Ben Azaiz, Ran
    de Larrea, Carlos Fernandez
    ANNALS OF HEMATOLOGY, 2025, 104 (02) : 1177 - 1186
  • [9] Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Vesole, David H.
    Bilotti, Elizabeth
    Richter, Joshua R.
    McNeill, Ann
    McBride, Laura
    Raucci, Laura
    Anand, Palka
    Bednarz, Urszula
    Ivanovski, Kristin
    Smith, Judith
    Batra, Veena
    Aleman, Adolfo
    Sims, Taliah
    Guerrero, Laura
    Mato, Anthony
    Siegel, David S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (01) : 52 - 59
  • [10] A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
    Alsina, Melissa
    Landgren, Ola
    Raje, Noopur
    Niesvizky, Ruben
    Bensinger, William I.
    Berdeja, Jesus G.
    Kovacsovics, Tibor
    Vesole, David H.
    Fang, Belle
    Kimball, Amy S.
    Siegel, David S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (02) : 226 - 233
12345